We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 09, 2022

CMB305 and Atezolizumab vs Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
J. Clin. Oncol 2022 Apr 20;40(12)1291-1300, SP Chawla, BA Van Tine, SM Pollack, KN Ganjoo, AD Elias, RF Riedel, S Attia, E Choy, SH Okuno, M Agulnik, M von Mehren, MB Livingston, VL Keedy, CF Verschraegen, T Philip, GC Bohac, S Yurasov, A Yakovich, H Lu, M Chen, RG Maki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading